China’s Lummy HK and the China BioPharma Capital I Fund have agreed to acquire $10 million worth of Durham, NC-based Argos Therapeutics stock in exchange for rights to develop and commercialize Argos’ AGS-003 personalized cancer drug in China, Hong Kong, Taiwan and Macau.

…read more

Source: Argos gets a $40M China deal for AGS-003


0 No comments